sNDA submission supports the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home (outpatient) setting with IGALMI ® Submission timeline supports potential ...
BioXcel Therapeutics Expands Leadership Team to Prepare for Launch of IGALMI® in the At-Home Setting
Mark Pavao to Join BioXcel Therapeutics as Interim Chief Commercial Officer Mr. Pavao Brings Deep Experience in Neuroscience Sales and Marketing to Support Potential Launch of IGALMI® in At-Home ...
Intranasal etripamil is the first self-administered, on-demand therapy for PSVT, allowing treatment outside healthcare settings. The RAPID trial showed 64% of etripamil-treated patients returned to ...
Before her surgery in Ann Arbor, Amy Benét’s left brachiocephalic vein was 100% constricted, while the right was between 92-95% closed. Doctors explained this stenosis was seriously restricting the ...
Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...
The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
In 2017, Matthew Williams, a thirtysomething software engineer with an athletic build and a bald head, went for a long bike ride in the hills of San Francisco. Afterward, at dinner with some friends, ...
NEW HAVEN, Conn., Aug. 19, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results